Jennifer N. Perusini, Ph.D.; Chief Executive Officer

Jennifer Perusini earned her B.A. in Neuroscience at Barnard College of Columbia University. She then received her Ph.D. in Behavioral Neuroscience at University of California, Los Angeles under the direction of Neurovation Labs co-founder Dr. Michael Fanselow, where she studied the mechanisms underlying Post-traumatic Stress Disorder (PTSD). Recently, she completed her post-doctoral fellowship at Columbia University in the Departments of Psychiatry and Integrative Neuroscience, where her research focused on rodent models of aging and Alzheimer’s disease. Dr. Perusini is now founder and CEO of Neurovation Labs. Her doctoral dissertation work forms the basis of the company’s research.

Michael S. Fanselow, Ph.D.; Director of Research

Michael Fanselow received his B.S. in Psychology from CUNY Brooklyn College and his Ph.D. from the University of Washington in Biobehavioral Psychology. He received the Edwin B. Newman Award for Excellence in Research for his dissertation work there. Dr. Fanselow is a Professor in the Department of Psychology at UCLA and has held academic appointments at Rennselaer Polytechnic Institute and Dartmouth College before coming to UCLA in 1987. He has also received the Early Career Distinguished Scientific Contribution Award, the D. O. Hebb Award from the American Psychological Association, the Troland Award from the National Academy of Science, and is a member of the honorary Society of Experimental Psychologists. He was elected President of the American Psychological Association’s Division of Behavioral Neuroscience and Comparative Psychology and President of the Pavlovian Society. He currently holds positions as the Staglin Family Chair and the Director of the Staglin Music Festival Center for Brain & Behavioral Health. His research focuses on the neurobiology of fear, anxiety & stress related behavior; he has developed the freezing assay of conditional fear, which has become one of the most widely-used tools in preclinical research of learning and memory in general, and fear and anxiety in particular. Dr. Fanselow’s lab has developed animal models of PTSD that capture several of the major components of this disorder, and he was Dr. Perusini’s graduate advisor. He has recently been appointed as Director of the Staglin Music Festival Center for Brain and Behavioral Health, whose mission is to conduct and facilitate research on the nature of mental disorders and develop pathways to restoring healthy brain function and adaptive behavior. Dr. Fanselow is co-founder and Director of Research at Neurovation Labs.

Richard P. Zemsky; Chief Operating Officer/ Legal

Richard P. Zemsky received a B.S. in Mechanical Engineering from Villanova University before graduating from Columbia Law School.  He founded Sproute Travel, a tech company for travel recommendations and trip planning.  Richard has previously conducted research in heat transfer theory, shape memory alloy-based robotic design, and sediment accumulation on mid-ocean ridges, and served as team lead for mechanical and aeronautical design for a vertical take-off and landing electric aircraft.  As an attorney he focused on patent law across a range of technologies, advising early stage and established companies in the development, protection, and enforcement of their intellectual property rights.  Mr. Zemsky is a co-founder of Neurovation Labs and COO.

Daniel G. Marren; Chief Financial Officer

Daniel Marren received his BBA in Accounting from the University of Notre Dame. He began his career in public accounting at Ernst & Whinney (now Ernst & Young) where he had a variety of international audit and consulting responsibilities, including IPOs for U.S. and foreign registrants. Subsequently, Daniel’s first startup was in 1988 and he has been active with startups and growth companies ever since, as a CEO, COO, CFO, consultant, investor, director, and/or adviser. Current and recent venture-backed activities and clients include FinTech, biotech, digital healthcare, hardware, wearable tech, SaaS, ecommerce, and certain insurance and reinsurance activities. Focusing on finance, operations, and strategy, he has helped to grow companies from conception to billion dollar operations. Mr. Marren is CFO of Neurovation Labs.

Jeremy Bloomer; Advising Member

Jeremy Bloomer received his MBA in 1985 from The Amos Tuck School of Business Administration at Dartmouth College and a B.A. in 1980 from the University of Pennsylvania. He has over 20 years of investment banking, merchant banking, and investment management experience encompassing investment banking, research, sales, and trading in distressed securities, high yield securities, and private equity of emerging and middle market companies. He began his career in 1980 as a Commercial Loan Officer first at Chemical Bank and then Chase Manhattan Bank. Currently, Mr. Bloomer is the CEO and founder of the specialty finance company Greenwich Life Settlements, managing member of the Ivy Group, a NASD broker/dealer merchant bank he founded, and Vice Chairman of the Board of the New Fund Institute for Cancer Research. Previously, he was senior portfolio manager at the Airlie Group and co-founder of the boutique institutional investment bank Credit and Research & Trading, LLC (CRT). Mr. Bloomer is on the Board of Directors of Neurovation Labs and is an advising member.

Michael W. Wood, Ph.D.; Advising Member

Michael Wood received his B.S. in Environmental Health from Oakland University in 1992 and his Ph.D. in Pharmacology/toxicology from Duke University in 1996. Following postdoctoral appointments at Harvard and Eli Lilly, he worked in CNS drug discovery at AstraZeneca for 18 years, holding a variety of scientific positions – section head, project leader – before moving into strategic roles – target team leader and collaboration director. He has directed or facilitated dozens of drug discovery projects across a variety of CNS indications at all stages of discovery. He recently established an independent drug discovery consultancy, Neupharm LLC. He has held executive positions in with the American Society of Pharmacology and Experimental Therapeutics for the last eight years and recently co-organized a colloquium on academic drug discovery in collaboration with the Academic Drug Discovery Consortia. Dr. Wood is on the Board of Directors of Neurovation Labs as an advising member.